Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VECTIBIX vs CYRAMZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Epidermal growth factor receptor (EGFR) antagonist; binds to EGFR and competitively inhibits ligand binding, leading to inhibition of downstream signaling pathways including RAS/RAF/MAPK and PI3K/AKT, resulting in cell cycle arrest and apoptosis.
Ramucirumab is a human Ig G1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.
Metastatic colorectal cancer (m CRC) with wild-type RAS (KRAS and NRAS) as first-line in combination with FOLFOX or as monotherapy after progression,Metastatic colorectal cancer (m CRC) with wild-type RAS as second-line in combination with irinotecan or as monotherapy after failure of irinotecan-based regimens
Gastric or gastroesophageal junction adenocarcinoma, as monotherapy or with paclitaxel,Non-small cell lung cancer (NSCLC), in combination with docetaxel,Metastatic colorectal cancer, in combination with FOLFIRI,Hepatocellular carcinoma (HCC), as monotherapy,Off-label: Advanced urothelial carcinoma, endometrial cancer
6 mg/kg IV every 14 days.
8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.
Terminal half-life approximately 7.5 days (range 3.6–10.9 days); supports every-2-week dosing regimen.
Terminal elimination half-life is approximately 14 days (range 11–17 days) at steady state, supporting a dosing interval of every 2 weeks.
Primarily eliminated via the reticuloendothelial system; not metabolized by cytochrome P450 enzymes; no significant hepatic metabolism.
Ramucirumab is a monoclonal antibody; metabolism is via catabolism into small peptides and amino acids (nonspecific proteolytic degradation). No major metabolic enzymes involved.
Primarily eliminated via the reticuloendothelial system; <3% excreted unchanged in urine; no significant renal or biliary elimination.
Ramucirumab is eliminated primarily via proteolytic catabolism; no renal or biliary excretion occurs. Clearance is 0.014 L/h (0.022 L/h with high VEGF), with a mean terminal half-life of 14 days (range 11–17 days) at steady state.
Approximately 95% bound, primarily to albumin; minimal binding to other plasma proteins.
Approximately 95% bound to serum proteins, primarily albumin and immunoglobulins.
Volume of distribution approximately 3.0–4.0 L/kg; suggests extensive tissue distribution and binding to EGFR-expressing cells.
Volume of distribution at steady state is approximately 5.0–6.0 L, corresponding to 0.07–0.09 L/kg (assuming 70 kg body weight), indicating limited extravascular distribution primarily within plasma volume.
Subcutaneous: Absolute bioavailability approximately 93% relative to intravenous administration.
Bioavailability is 100% as ramucirumab is administered only by intravenous infusion; no oral or other form is available.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not studied in severe renal impairment or dialysis.
No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Insufficient data for severe (Child-Pugh C) hepatic impairment.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). For moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment, no dosing information available; use with caution.
Safety and efficacy not established in pediatric patients.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment recommended; no significant differences in safety or efficacy observed in patients ≥65 years compared to younger adults.
No dose adjustment required based on age. Monitor for increased risk of adverse events such as hypertension, hemorrhage, and gastrointestinal perforations.
None.
Hemorrhage: Severe or fatal hemorrhage, including gastrointestinal hemorrhage, hemoptysis, and intracranial hemorrhage, has occurred. Do not administer in patients with severe bleeding.
Infusion reactions (including severe and fatal), dermatologic toxicity (including severe acneiform dermatitis and infections), increased toxicity with concurrent chemotherapy (especially diarrhea and dehydration), pulmonary fibrosis, hypomagnesemia, ocular toxicity, and potential for fetal harm.
Hemorrhage risk: Serious and sometimes fatal hemorrhagic events; permanently discontinue if severe bleeding occurs.,Arterial thromboembolic events: Including myocardial infarction and stroke; discontinue if occurs.,Gastrointestinal perforation: Fatal cases reported; discontinue if occurs.,Impaired wound healing: Interrupt therapy 28 days prior to elective surgery; do not resume until wound fully healed.,Hypertension: Monitor blood pressure; treat with antihypertensives; temporarily withhold if severe hypertension occurs.,Proteinuria: Monitor urine protein; withhold for >2 g/24h; discontinue if nephrotic syndrome develops.,Hypersensitivity/infusion reactions: Permanently discontinue if severe reaction occurs.,Thyroid dysfunction: Monitor thyroid function during treatment.
None known.
Severe hemorrhage (active bleeding),Hypersensitivity to ramucirumab or any excipients
No specific food interactions are reported. However, because diarrhoea is common, patients may need to adjust their diet to manage symptoms (e.g., avoid high-fiber, fatty, or spicy foods). Adequate hydration and electrolyte replacement are essential if diarrhoea occurs. No restrictions on grapefruit juice or other CYP3A4 substrates; VECTIBIX is not metabolized by CYP enzymes.
No specific food interactions are documented. Avoid grapefruit juice if taking concomitant drugs metabolized by CYP3A4 (e.g., simvastatin) due to potential interaction, but no direct interaction with ramucirumab.
Pregnancy Category C. Panitumumab is an Ig G2 monoclonal antibody; Ig G crosses the placenta, with the highest transfer occurring in the third trimester. Based on its mechanism of EGFR inhibition, there is potential for fetal harm. Animal studies (cynomolgus monkeys) with panitumumab at doses 0.5 to 5 times the clinical exposure (AUC) revealed embryotoxicity and developmental delays (e.g., skeletal malformations, increased abortions). No adequate human studies exist. Use only if potential benefit justifies risk; avoid in pregnancy unless absolutely necessary.
Cyramza (ramucirumab) is a VEGF receptor antagonist. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to pregnant women. In animal reproduction studies, intravenous administration of ramucirumab to pregnant rabbits during organogenesis resulted in embryofetal mortality and reduced fetal weight at exposures less than the recommended human dose. There are no adequate and well-controlled studies in pregnant women. Cyramza is contraindicated in pregnancy. First trimester: High risk of teratogenicity; VEGF inhibition interferes with embryonic vascular development. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and potential for fetal renal impairment due to anti-angiogenic effects. Avoid use during pregnancy.
No data on presence in human milk, effects on breastfed infant, or milk production. Human Ig G is excreted in breast milk, but panitumumab is a large protein likely degraded in infant GI tract. M/P ratio unknown. Because of potential for serious adverse reactions in nursing infants, advise women to discontinue breastfeeding during treatment and for 2 months after last dose.
No human data available on the presence of ramucirumab in human milk, effects on the breastfed infant, or effects on milk production. Ramucirumab is a large protein molecule (Ig G1 monoclonal antibody) and is likely to be present in breast milk at low levels, especially in early postpartum period. However, because of the potential for serious adverse reactions in the breastfed infant, advise women not to breastfeed during treatment and for at least 2 months after the last dose. M/P ratio: Not determined.
No pharmacokinetic data in pregnancy; no established dose adjustments. Usual dose: 6 mg/kg IV every 14 days. If used during pregnancy, monitor maternal toxicities closely (e.g., skin, electrolytes) and consider dose reduction or discontinuation based on toxicity. No specific dose modification guidelines exist for pregnancy.
Cyramza is contraindicated in pregnancy; no dosing adjustments are recommended as use should be avoided. If used inadvertently, no specific pharmacokinetic data in pregnancy are available; however, physiological changes (e.g., increased plasma volume, altered renal function) may affect drug clearance, but no dose adjustment guidelines exist. The risk of fetal harm outweighs any potential benefit, and treatment should be discontinued immediately if pregnancy occurs.
VECTIBIX (panitumumab) is a fully human monoclonal antibody targeting EGFR. It is indicated for RAS wild-type metastatic colorectal cancer (m CRC). Always confirm RAS wild-type status (no mutations in KRAS/NRAS) before initiation. Infusion reactions are common; premedicate with antihistamine and acetaminophen for first dose. Monitor for dermatologic toxicity (rash, paronychia, dry skin) which is a class effect and may correlate with efficacy. Electrolyte abnormalities, particularly hypomagnesemia, can occur; monitor serum magnesium weekly during therapy and for 8 weeks after completion. Avoid use in patients with RAS mutant tumors due to lack of benefit and potential harm. VECTIBIX is not effective in tumors with BRAF V600E mutation.
CYRAMZA (ramucirumab) is a VEGFR-2 antagonist; premedicate with antihistamines and acetaminophen before infusion to reduce infusion-related reactions. Monitor blood pressure closely as hypertension is common; hold for severe hypertension. Avoid use in patients with significant bleeding risk or recent thromboembolic events. Do not administer with platinum-based chemotherapy in NSCLC patients with EGFR or ALK mutations unless progression on targeted therapy.
This medication targets the epidermal growth factor receptor (EGFR) on cancer cells and is used for metastatic colorectal cancer with a specific genetic profile (RAS wild-type).,You will need genetic testing for RAS mutations (KRAS/NRAS) before starting treatment to ensure the drug is appropriate.,Common side effects include skin rash, dry skin, itching, nail infections, and diarrhea. The skin rash may be a sign the drug is working but requires management.,Report any signs of infusion reaction (chills, fever, shortness of breath, flushing) during or after the infusion.,Serious side effects include severe infusion reactions, lung inflammation (interstitial lung disease), and low magnesium levels (muscle cramps, fatigue, irregular heartbeat). You will have regular blood tests to monitor magnesium and other electrolytes.,Avoid sun exposure and use sunscreen, as the drug increases skin sensitivity to sunlight.,Drink plenty of fluids to prevent dehydration from diarrhea, and notify your doctor if diarrhea is severe or persistent.,Do not receive any vaccines without consulting your doctor, especially live vaccines.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. Effective contraception should be used during treatment and for at least 2 months after the last dose.
You may experience high blood pressure; monitor regularly and report symptoms like severe headache or vision changes.,This drug can increase bleeding risk; inform your doctor if you have any unusual bruising or bleeding.,Infusion reactions may occur; you will receive premedication to reduce this risk.,Report any new or worsening shortness of breath, chest pain, or leg swelling as these could be signs of blood clots or heart problems.,Wound healing may be impaired; avoid elective surgery during treatment and inform all healthcare providers you are on this medication.,Effective contraception is required during treatment and for at least 3 months after final dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VECTIBIX vs CYRAMZA, answered by our medical review team.
VECTIBIX is a Antineoplastic Monoclonal Antibody that works by Epidermal growth factor receptor (EGFR) antagonist; binds to EGFR and competitively inhibits ligand binding, leading to inhibition of downstream signaling pathways including RAS/RAF/MAPK and PI3K/AKT, resulting in cell cycle arrest and apoptosis.. CYRAMZA is a Antineoplastic Monoclonal Antibody that works by Ramucirumab is a human Ig G1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VECTIBIX and CYRAMZA depend on the specific clinical indication. These are both Antineoplastic Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VECTIBIX is: 6 mg/kg IV every 14 days.. The standard adult dose of CYRAMZA is: 8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VECTIBIX and CYRAMZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VECTIBIX is classified as Category C. Pregnancy Category C. Panitumumab is an IgG2 monoclonal antibody; IgG crosses the placenta, with the highest transfer occurring in the third trimester. Based on its mechanism of EG. CYRAMZA is classified as Category C. Cyramza (ramucirumab) is a VEGF receptor antagonist. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to pregnant women. In animal rep. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.